Luigi Moro

Appearances

PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PROOF OF CONCEPT STUDY OF EFFICACY OF RIFAMYCIN SV-MMX® 600 MG ADMINISTERED THREE OR TWO TIMES DAILY TO PATIENTS WITH DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS-D)
Date
May 18, 2024
INTRODUCTION: Irritable bowel syndrome (IBS) is a common disorder of gut-brain interaction characterized by abdominal pain associated with bowel movements…
Presenter
Lukas M. Balsiger
Speakers
Javier Santos
Jordi Serra
Hubert Piessevaux
Didier Baert
Martin Storr
Guido Basilisco
Alessandro Mazzetti
Luigi Moro
Mara Gerloni
Luigi Longo
Alessandra Gentili
Jan Tack